Trial Profile
A phase II safety and efficacy study of bavituximab plus paclitaxel and carboplatin in patients with locally advanced or metastatic breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2011
Price :
$35
*
At a glance
- Drugs Bavituximab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 22 Nov 2011 Results have been presented in a Peregrine Pharmaceuticals media release.
- 23 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Mar 2011 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.